Hansa Biopharma AB (HNSA) Stock Statistics & Valuation Metrics

Hansa Biopharma AB has a market cap or net worth of kr2.38B. The enterprise value is kr2.98B.

Hansa Biopharma AB has 84,763,220 shares outstanding. The number of shares has decreased by -2.65% in one year.

Hansa Biopharma AB’s return on equity (ROE) is 1.37 and return on invested capital (ROIC) is -115.86%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Hansa Biopharma AB had revenue of 171.32M and earned -807.24M in profits. Earnings per share was -12.84.

In the last 12 months, operating cash flow was -696.65M and capital expenditures -628.00K, giving a free cash flow of -697.28M billion.

Hansa Biopharma AB pays an annual dividend of ―, resulting in a dividend yield of ―

Hansa Biopharma AB upcoming earnings date is Oct 23, 2025, Before Open (Confirmed).

Hansa Biopharma AB as a current ratio of 2.29, with Debt / Equity ratio of -163.23%

In the past 12 months, Hansa Biopharma AB has paid 3.03M in taxes.

Hansa Biopharma AB EV to EBITDA ratio is -4.89, with an EV/FCF ratio of -4.65.

Hansa Biopharma AB has kr250.20M in cash and marketable securities with kr1.02B in debt, giving a net cash position of kr767.93M billion.

Gross margin is 52.71%, with operating margin of -372.34%, and net profit margin of -471.20%.

The average price target for Hansa Biopharma AB is kr143.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy